Therapeutic Antibodies

Introduced by Drs. Freda K. Stevenson and Catherine M. Bollard, this series of 6 reviews written by leaders in the field describe the emerging mechanistic insights and therapeutic value of different classes of antibody therapy, including direct antibodies; “accelerator” antibodies against coreceptors; and antibodies reversing regulatory T-cell activity, for a variety of hematological malignancies.

Review Series Articles:

Introduction to a review series on therapeutic antibodies
Freda K. Stevenson and Catherine M. Bollard

CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk, Paul G. Richardson and Fabio Malavasi

 

Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez, Challice L. Bonifant and Stephen Gottschalk

 

The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Sarah L. Buchan, Anne Rogel and Aymen Al-Shamkhani

 

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategiess
Cariad Chester, Miguel F. Sanmamed, Jun Wang and Ignacio Melero

 

CTLA-4: a moving target in immunotherapy
Behzad Rowshanravan, Neil Halliday and David M. Sansom

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette, Jianfeng Zhou and Ken H. Young